scholarly journals Interim Prosthetic Rehabilitation of a Patient Following Partial Rhinectomy: A Clinical Report

2010 ◽  
Vol 04 (04) ◽  
pp. 482-486 ◽  
Author(s):  
Satyabodh S. Guttal ◽  
Paras Vohra ◽  
Lekha K. Pillai ◽  
Ramesh K. Nadiger

Surgical defects often have adverse effects on patient perception of esthetics and self-esteem. Rehabilitation of such surgical defects poses a challenge to the clinician. Presented here is a clinical report of an interim prosthetic rehabilitation of a patient who underwent partial rhinectomy for basal cell carcinoma. Nasal resection included part of the nasal septum, the entire cartilage, and the ala. An interim nasal prosthesis was fabricated for this patient 3 weeks after surgery, to provide early rehabilitation. This prosthesis provided a sociopsychological benefit to the patient, and the prosthesis was well tolerated. The spectacle glasses retained the prosthetic nose. (Eur J Dent 2010;4:482-486)

Dermatology ◽  
2015 ◽  
Vol 231 (1) ◽  
pp. 56-62 ◽  
Author(s):  
Rick Waalboer-Spuij ◽  
Cynthia Holterhues ◽  
Simone van Hattem ◽  
Marie Louise A. Schuttelaar ◽  
Menno T.W. Gaastra ◽  
...  

2021 ◽  
pp. 120347542110512
Author(s):  
Justin Tong ◽  
Brandon Mitchell ◽  
Kathryn Roth ◽  
Diane Logan ◽  
Scott Ernst

Background Vismodegib is a novel Hedgehog pathway inhibitor that has revolutionized the treatment of patients with advanced basal cell carcinoma (BCC) who are poor candidates for surgery or radiation. Few studies have explored the use of vismodegib to facilitate further surgery or radiotherapy, and the optimal treatment duration to balance outcomes with adverse effects. Objectives To characterize the disease response, progression, and recurrence outcomes of BCC patients, and to report the impact of subsequent therapies. Methods We performed a retrospective study of 46 adult patients with advanced basal cell carcinoma (aBCC), including both locally advanced (laBCC) and metastatic (mBCC) disease, treated with vismodegib at a single center from 2012 to 2019. Results Thirty-six had laBCC, and 10 had mBCC. Treatment was given over a mean of 21.9 months. Twenty-three (50%) had a complete response (CR), and 19 (41.3%) achieved partial response (PR). Median time to maximal response was 5.3 months. Eleven (23.9%) had resected disease at median 17.2 months, and 11 patients (23.9%) received radiotherapy. Thirty-two (69.6%) experienced progressive disease after achievement of CR or PR. Among 17 CR patients, who stopped treatment, 14 (82.3%) experienced subsequent relapse; 6 (85%) attained a repeat response. Twenty (43.5%) discontinued treatment at least once due to adverse effects. Conclusions With a response rate of 91%, London Regional Cancer Center’s (LRCP)’s experience with vismodegib supports its effectiveness in treatment of aBCC. Moreover, a significant number of patients treated with vismodegib became amenable to surgery or radiotherapy. Toxicity remained an important factor that limited treatment duration.


Sign in / Sign up

Export Citation Format

Share Document